Eupraxia Pharmaceuticals’ (EPRX) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Eupraxia Pharmaceuticals (NASDAQ:EPRX) in a research note issued to investors on Thursday morning, MarketBeat Ratings reports. They currently have a $11.00 price target on the stock.

Other research analysts have also issued research reports about the stock. Oppenheimer initiated coverage on shares of Eupraxia Pharmaceuticals in a research note on Thursday, June 25th. They set an “outperform” rating and a $17.00 price objective on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a research report on Friday, July 17th. Cantor Fitzgerald restated an “overweight” rating on shares of Eupraxia Pharmaceuticals in a research report on Wednesday, July 15th. Wall Street Zen upgraded Eupraxia Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Saturday, September 12th. Finally, Stifel Nicolaus set a $25.00 target price on Eupraxia Pharmaceuticals in a research note on Thursday, September 24th. Two analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $17.80.

Eupraxia Pharmaceuticals Stock Down 7.5%

Shares of Eupraxia Pharmaceuticals stock opened at $7.24 on Thursday. The company has a quick ratio of 16.00, a current ratio of 16.00 and a debt-to-equity ratio of 0.02. Eupraxia Pharmaceuticals has a 12 month low of $5.25 and a 12 month high of $9.32. The business has a fifty day simple moving average of $7.37 and a 200 day simple moving average of $7.02. The stock has a market cap of $470.74 million, a PE ratio of -7.10 and a beta of 0.83.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last released its earnings results on Tuesday, August 11th. The company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.02. Research analysts predict that Eupraxia Pharmaceuticals will post -0.85 EPS for the current year.

Institutional Trading of Eupraxia Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in EPRX. Seven Fleet Capital Management LP bought a new stake in shares of Eupraxia Pharmaceuticals in the 1st quarter valued at about $5,137,000. Redmile Group LLC bought a new position in Eupraxia Pharmaceuticals during the first quarter worth about $5,068,000. Rubric Capital Management LP acquired a new position in Eupraxia Pharmaceuticals during the first quarter worth approximately $5,004,000. Cibc World Market Inc. acquired a new position in Eupraxia Pharmaceuticals during the second quarter worth approximately $1,539,000. Finally, DV Trading LLC acquired a new position in Eupraxia Pharmaceuticals during the first quarter worth approximately $1,998,000.

Eupraxia Pharmaceuticals Company Profile

Eupraxia Pharmaceuticals Inc (NASDAQ:EPRX) is a Canadian clinical-stage biotechnology company focused on developing locally delivered therapies designed to treat disease at the site of action while potentially reducing systemic exposure and associated side effects. The company is headquartered in Victoria, British Columbia, and is developing candidates for inflammatory and other serious medical conditions.

Eupraxia’s lead program, EP-262, is an extended-release formulation of dexamethasone being developed for the treatment of pain and inflammation associated with osteoarthritis of the knee.